Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications
Centessa Pharmaceuticals plc - American Depositary Shares (CNTA)
Company Research
Source: GlobeNewswire
BOSTON and LONDON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today announced that its Board of Directors has appointed Mario Alberto Accardi PhD, President and founder of Centessa’s Orexin Program, as Chief Executive Officer (CEO) and member of the Board, effective January 1, 2026. Dr. Accardi will succeed Saurabh Saha MD PhD, who will step down from his position as CEO and a member of the Board, effective January 1, 2026. Dr. Saha will be appointed advisor to the CEO. “This leadership transition underscores Centessa’s strategic evolution from an R&D driven start-up with a diversified early-stage pipeline to an organization focused on advancing a pure-play orexin portfolio positioned at the forefront of this rapidly emerging therapeutic class,” said Francesco De Rubertis PhD, Chair of Centessa’s Board. “This strategic focus has enabled a robust pipeline of potential best-in-class OX2R agonists for a broad
Show less
Read more
Impact Snapshot
Event Time:
CNTA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CNTA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CNTA alerts
High impacting Centessa Pharmaceuticals plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
CNTA
News
- Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications [Yahoo! Finance]Yahoo! Finance
- Centessa Pharmaceuticals (NASDAQ:CNTA) is now covered by analysts at Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $62.00 price target on the stock.MarketBeat
- Analysts Boost Centessa Pharmaceuticals plc (CNTA) Price Targets as Sleep Disorder Drug Shows Breakthrough Results [Yahoo! Finance]Yahoo! Finance
- Centessa Pharmaceuticals (NASDAQ:CNTA) had its price target raised by analysts at B. Riley from $33.00 to $42.00. They now have a "buy" rating on the stock.MarketBeat
- Centessa Pharmaceuticals (NASDAQ:CNTA) was upgraded by analysts at Chardan Capital to a "strong-buy" rating.MarketBeat
CNTA
Earnings
- 8/12/25 - Miss
CNTA
Sec Filings
- 12/11/25 - Form 8-K
- 12/9/25 - Form 4
- 12/9/25 - Form 144
- CNTA's page on the SEC website